A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study
Journal of Comparative Effectiveness Research · 2026-04 · 15 (4)
DOI: 10.57264/cer-2025-0134 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-04. Verfasst von Richard Scott Swain und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cardinal Health, Dublin, OH 43017, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FDA HHS.
Abstract (Originalsprache)
Aim
In oncology trials, blinded independent central review (BICR) is the standard for treatment response classification. Real-world data methodologies that align with BICR may reduce misclassification in real-world evidence (RWE) studies and enhance reproducibility, increasing value of RWE. We aimed to develop and validate a novel real-world data-based methodology – real-world Lugano (rwLugano) – for assessing lymphoma response to align with clinical trials. Materials & methods: We conducted a retrospective, multisite chart abstraction study using Cardinal Health Practice Research Network (PRN) sites to identify adults with diffuse large B-cell lymphoma initiating first-line (1L) therapy from 1 January 2015, through 31 December 2022, in US community oncology. Sites collected patient characteristics and PET/CT scans at baseline and first response. Two radiologists independently classified responses; a medical oncologist adjudicated discordances.
Results
We compared initial treatment responses using three methods: physician-charted from electronic health records, rwLugano-derived per Lugano 2014 and BICR-adjudicated per Lugano 2014. Agreement was assessed via percentage concordance, kappa (κ), and multivariable generalized linear mixed modeling for assigning complete response (CR). Among 178 patients, CR rates were 63.5% (physician-charted), 81.5% (rwLugano) and 83.1% (BICR). Compared with BICR, rwLugano showed higher agreement (87.9%, κ = 0.52) than physician-charted (77.0%, κ = 0.40). The generalized linear mixed modeling analyses identified clinical factors associated with concordance: for physician charted assessments, greater numbers of extranodal sites increased agreement with BICR (OR 1.92), while MYC mutation (OR 0.38) and anemia (OR 0.37) reduced agreement. For rwLugano, nonprivate insurance was associated with higher agreement (odds ratio [OR]: 4.40), whereas MYC mutation reduced agreement (OR: 0.26). Conclusion: rwLugano improves real-world lymphoma response classification, aligning with BICR and supporting more accurate, reproducible RWE for clinical and regulatory decision-making. Using methods BICR and rwLugano may provide opportunities to minimize outcome misclassification and improve comparability of clinical trial and clinical practice approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardinal Health, Dublin, OH 43017, USA.
- Office of Oncologic Disease, US Food & Drug Administration, Silver Spring, MD 20993, USA.
- Oncology Center of Excellence, US Food & Drug Administration, Silver Spring, MD 20993, USA.
- Office of Biostatistics, US Food & Drug Administration, Silver Spring, MD 20993, USA.
ORCID-Profile: Richard Scott Swain, Andrew Klink, Parisa Asgarisabet, Kristin M Zimmerman Savill, Bindu Kalesan, Alexandrina Balanean, Lindsay McAllister, Courtney Omary, Hsing-Ting Yu, JaLyna Laney, Nicholas C Richardson, Catherine C Lerro, Jonathon Vallejo, Donna R Rivera, Bruce A Feinberg
Förderung
- FDA HHS
Zitieren
APA
Swain, R. S., Klink, A., Asgarisabet, P., Zimmerman Savill, K. M., Kalesan, B., Balanean, A., Hays, H., Kaufman, J., McAllister, L., Omary, C., Yu, H. T., Laney, J., Richardson, N. C., Lerro, C. C., Rizvi, F., Vallejo, J., Wang, K., Theoret, M. R., Rivera, D. R., & Feinberg, B. A. (2026). A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study. Journal of Comparative Effectiveness Research, 15(4). https://doi.org/10.57264/cer-2025-0134
Vancouver
Swain RS, Klink A, Asgarisabet P, Zimmerman Savill KM, Kalesan B, Balanean A, et al. A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study. Journal of Comparative Effectiveness Research. 2026;15(4). doi:10.57264/cer-2025-0134
BibTeX
@article{Swain2026,
author = {Swain, Richard Scott and Klink, Andrew and Asgarisabet, Parisa and Zimmerman Savill, Kristin M and Kalesan, Bindu and Balanean, Alexandrina and Hays, Harlen and Kaufman, Jill and McAllister, Lindsay and Omary, Courtney and Yu, Hsing-Ting and Laney, JaLyna and Richardson, Nicholas C and Lerro, Catherine C and Rizvi, Fatima and Vallejo, Jonathon and Wang, Kun and Theoret, Marc R and Rivera, Donna R and Feinberg, Bruce A},
title = {A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study},
journal = {Journal of Comparative Effectiveness Research},
year = {2026},
volume = {15},
number = {4},
doi = {10.57264/cer-2025-0134}
}
EUVIMED